eXoZymes, Inc.
$9.46
-2.2%eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.7).
Valuation inputs: P/E -8.7, earnings yield N/A, momentum -2.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.7%, ROIC -2.0%).
Profitability stack: net margin 0.0%, ROE -2.7%, ROIC -2.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +43.1%, momentum -2.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
eXoZymes, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
eXoZymes, Inc. Fair Value Envelope
No Revenue Data
EXOZ has not reported any revenue values in the available annual periods.
eXoZymes, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
EXOZ has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
EXOZ has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
EXOZ has not reported any net profit margin values in the available annual periods.
eXoZymes, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
eXoZymes, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
eXoZymes, Inc. Street Expectations Map
No Target Data
No analyst price targets available for exoz.
eXoZymes, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.05M and sold $15K worth of EXOZ shares, resulting in $3.04M of net buying activity.
3 Months
0
0.00
1.5K
15.42K
-15K
-$15K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
246.3K
3.05M
0
0.00
+3.1M
+$3.05M
Top Buyers
Heltzen Michael
Officer: Chief Executive Officer
$2.93M
Nawaz Fouad
Officer: Vice President, Finance
$44K
Korman Tyler Paz
Officer: Vice President, Research
$37K
Opgenorth Paul Hideo
Officer: Vice President, Development
$37K
Top Sellers
Korman Tyler Paz
Officer: Chief Scientific Officer
$15K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $3.04M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
EXOZ has not reported any dividend yield values in the available annual periods.
exoz Dividend History
Learning Layer
Related Guides
Build conviction on EXOZ by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.